Citations (59)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Maria P. Yavropoulou, Polyzois Makras & Athanasios D. Anastasilakis. (2019) Bazedoxifene for the treatment of osteoporosis. Expert Opinion on Pharmacotherapy 20:10, pages 1201-1210.
Read now
Read now
Koji Ishikawa, Takashi Nagai, Keizo Sakamoto, Kenji Ohara, Takeshi Eguro, Hiroshi Ito, Yoichi Toyoshima, Akatsuki Kokaze, Tomoaki Toyone & Katsunori Inagaki. (2016) High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Therapeutics and Clinical Risk Management 12, pages 1831-1840.
Read now
Read now
Tanya A Enderli, Stephanie R Burtch, Jara N Templet & Alessandra Carriero. (2016) Animal models of osteogenesis imperfecta: applications in clinical research. Orthopedic Research and Reviews 8, pages 41-55.
Read now
Read now
Josep Darbà, Lisette Kaskens, Francesc Sorio Vilela & Mickael Lothgren. (2015) Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain. ClinicoEconomics and Outcomes Research 7, pages 105-117.
Read now
Read now
Barry S Komm, Diana Morgenstern, Luis A Yamamoto & Simon N Jenkins. (2015) The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women. Expert Review of Clinical Pharmacology 8:6, pages 769-784.
Read now
Read now
Colby A Souders, Stuart C Nelson, Yang Wang, Andrew R Crowley, Mark S Klempner & William Thomas$suffix/text()$suffix/text(). (2015) A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. mAbs 7:5, pages 912-921.
Read now
Read now
Leos Fuksa & Magda Vytrisalova. (2015) Adherence to denosumab in the treatment of osteoporosis and its utilization in the Czech Republic. Current Medical Research and Opinion 31:9, pages 1645-1653.
Read now
Read now
Garry M Walsh. (2012) Treatment options for postmenopausal osteoporosis. Therapeutics and Clinical Risk Management 8, pages 367-368.
Read now
Read now
Articles from other publishers (51)
Aleena Anwar, Leena Sapra, Navita Gupta, Rudra P. Ojha, Bhupendra Verma & Rupesh K. Srivastava. (2023) Fine‐tuning osteoclastogenesis: An insight into the cellular and molecular regulation of osteoclastogenesis. Journal of Cellular Physiology 238:7, pages 1431-1464.
Crossref
Crossref
Anthony Colella, Elaine Yu, Paul Sambrook, Toby Hughes & Alastair Goss. (2023) What is the Risk of Developing Osteonecrosis Following Dental Extractions for Patients on Denosumab for Osteoporosis?. Journal of Oral and Maxillofacial Surgery 81:2, pages 232-237.
Crossref
Crossref
Riyad N. H. Seervai, Sarah K. Friske, Emily Y. Chu, Rhea Phillips, Kelly C. Nelson, Auris Huen, Woo Cheal Cho, Phyu P. Aung, Carlos A. Torres‐Cabala, Victor G. Prieto & Jonathan L. Curry. (2022) The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy. Journal of Cutaneous Pathology 50:1, pages 72-95.
Crossref
Crossref
Ahmadreza Jamshidi, Mahdi Vojdanian, Mohsen Soroush, Mahmoud Akbarian, Mehrdad Aghaei, Asghar Hajiabbasi, Zahra Mirfeizi, Alireza Khabbazi, Gholamhosein Alishiri, Anousheh Haghighi, Ahmad Salimzadeh, Hadi Karimzadeh, Fatemeh Shirani, Mohammad Reza Hatef Fard, MohammadAli Nazarinia, Soosan Soroosh, Nassim Anjidani & Farhad Gharibdoost. (2022) Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial. Arthritis Research & Therapy 24:1.
Crossref
Crossref
Vishu Upmanyu, Leena Sapra & Rupesh K. Srivastava. 2022. Bioactive Natural Products. Bioactive Natural Products
161
241
.
Yasser El Miedany. 2022. New Horizons in Osteoporosis Management. New Horizons in Osteoporosis Management
491
524
.
T. Hasegawa, N. Ueda, SI. Yamada, S. Kato, E. Iwata, S. Hayashida, Y. Kojima, M. Shinohara, I. Tojo, H. Nakahara, T. Yamaguchi, T. Kirita, H. Kurita, Y. Shibuya, S. Soutome & M. Akashi. (2021) Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: a multicenter retrospective study. Osteoporosis International 32:11, pages 2323-2333.
Crossref
Crossref
Yumejiro Nakamura, Tomohiro Shimizu, Tsuyoshi Asano, Shun Shimodan, Hotaka Ishizu, Daisuke Takahashi, Masahiko Takahata & Norimasa Iwasaki. (2021) Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis. Journal of Bone and Mineral Metabolism 39:5, pages 824-832.
Crossref
Crossref
Yan Li, Bolei Cai, Zhaoyichun Zhang, Guanlin Qu, Lu Chen, Guojun Chen, Tingxizi Liang, Chi Yang, Ling Fan & Zhiyuan Zhang. (2021) Salicylic acid-based nanomedicine with self-immunomodulatory activity facilitates microRNA therapy for metabolic skeletal disorders. Acta Biomaterialia 130, pages 435-446.
Crossref
Crossref
D. Hadaya, A. Soundia, I. Gkouveris, O. Bezouglaia, S.M. Dry, F.Q. Pirih, T.L. Aghaloo & S. Tetradis. (2021) Antiresorptive-Type and Discontinuation-Timing Affect ONJ Burden. Journal of Dental Research 100:7, pages 746-753.
Crossref
Crossref
Martin Blomberg Jensen, Christine Hjorth Andreassen, Anne Jørgensen, John Erik Nielsen, Li Juel Mortensen, Ida Marie Boisen, Peter Schwarz, Jorma Toppari, Roland Baron, Beate Lanske & Anders Juul. (2021) RANKL regulates male reproductive function. Nature Communications 12:1.
Crossref
Crossref
Ioannis PapadakisAlexandra SpanouDemos Kalyvas. (2021) Success Rate and Safety of Dental Implantology in Patients Treated With Antiresorptive Medication: A Systematic Review. Journal of Oral Implantology 47:2, pages 169-180.
Crossref
Crossref
Michael R. McClung. 2021. Marcus and Feldman's Osteoporosis. Marcus and Feldman's Osteoporosis
1737
1755
.
Long Zhou, Hanyi Song, Yiqi Zhang, Zhaozhou Ren, Minghe Li & Qin Fu. (2020) Polyphyllin VII attenuated RANKL-induced osteoclast differentiation via inhibiting of TRAF6/c-Src/PI3K pathway and ROS production. BMC Musculoskeletal Disorders 21:1.
Crossref
Crossref
Ji-Yoon Noh, Young Yang & Haiyoung Jung. (2020) Molecular Mechanisms and Emerging Therapeutics for Osteoporosis. International Journal of Molecular Sciences 21:20, pages 7623.
Crossref
Crossref
Zi Zou, Wei Liu, Lihua Cao, Ying Liu, Tiantian He, Shuping Peng & Cijun Shuai. (2020) Advances in the occurrence and biotherapy of osteoporosis. Biochemical Society Transactions 48:4, pages 1623-1636.
Crossref
Crossref
Linda Sequeira, John Nguyen, Liyun Wang & Anja Nohe. (2020) A Novel Peptide, CK2.3, Improved Bone Formation in Ovariectomized Sprague Dawley Rats. International Journal of Molecular Sciences 21:14, pages 4874.
Crossref
Crossref
Ning Zhang, Zong-Kang Zhang, Yuanyuan Yu, Zhenjian Zhuo, Ge Zhang & Bao-Ting Zhang. (2020) Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Satoe Okuma, Yuhei Matsuda, Yoshiki Nariai, Masaaki Karino, Ritsuro Suzuki & Takahiro Kanno. (2020) A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers. Cancers 12:5, pages 1209.
Crossref
Crossref
Soo Min Jang, Smitha Anam, Tara Pringle, Paul Lahren & Sergio Infante. (2020) Contrasting PTH Response of Denosumab Use in Dialysis Patients: A Report of 2 Cases. Pharmacy 8:2, pages 59.
Crossref
Crossref
Anna Yuan, Adelheid Munz, Siegmar Reinert & Sebastian Hoefert. (2020) Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 129:2, pages 133-140.
Crossref
Crossref
Jordana Friedman, Aletia Farmer & Jacqueline Carey Fister. 2020. Sex- and Gender-Based Women's Health. Sex- and Gender-Based Women's Health
393
404
.
Stergios A. Polyzos, Polyzois Makras, Symeon Tournis & Athanasios D. Anastasilakis. (2019) Off-label uses of denosumab in metabolic bone diseases. Bone 129, pages 115048.
Crossref
Crossref
Leili Aghebati‐Maleki, Sanam Dolati, Reza Zandi, Ali Fotouhi, Majid Ahmadi, Ali Aghebati, Mohammad Nouri, Seyed Kazem Shakouri & Mehdi Yousefi. (2018) Prospect of mesenchymal stem cells in therapy of osteoporosis: A review. Journal of Cellular Physiology 234:6, pages 8570-8578.
Crossref
Crossref
Tsuyoshi Asano, Tomohiro Shimizu, Daisuke Takahashi, Masahiro Ota, Dai Sato, Hiroki Hamano, Shigeto Hiratsuka, Masahiko Takahata & Norimasa Iwasaki. (2018) Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol. Journal of Bone and Mineral Metabolism 37:2, pages 351-357.
Crossref
Crossref
Stergios A. Polyzos & Evangelos Terpos. (2018) Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis. Endocrine 62:2, pages 487-489.
Crossref
Crossref
Suad Aljohani, Robert Gaudin, Julian Weiser, Matthias Tröltzsch, Michael Ehrenfeld, Gabriele Kaeppler, Ralf Smeets & Sven Otto. (2018) Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series. Journal of Cranio-Maxillofacial Surgery 46:9, pages 1515-1525.
Crossref
Crossref
Harshika Awasthi, Dayanandan Mani, Divya Singh & Atul Gupta. (2018) The underlying pathophysiology and therapeutic approaches for osteoporosis. Medicinal Research Reviews 38:6, pages 2024-2057.
Crossref
Crossref
Lubinda Mbundi, Steve Meikle, Rosa Busquets, Nicholas Dowell, Mara Cercignani & Matteo Santin. (2018) Gadolinium Tagged Osteoprotegerin-Mimicking Peptide: A Novel Magnetic Resonance Imaging Biospecific Contrast Agent for the Inhibition of Osteoclastogenesis and Osteoclast Activity. Nanomaterials 8:6, pages 399.
Crossref
Crossref
Stergios A. Polyzos & Christos S. Mantzoros. (2018) Outliers of bone metabolic diseases. Metabolism 80, pages 1-4.
Crossref
Crossref
Brian J. King, Julia S. Lehman & Julio C. Sartori Valinotti. (2018) Denosumab-induced cutaneous hypersensitivity reaction with distinct clinical and histopathologic findings. Journal of Cutaneous Pathology 45:2, pages 156-158.
Crossref
Crossref
Sun Kyoung Lee, Hyungkeun Kim, Junhee Park, Hyun-Jeong Kim, Ki Rim Kim, Seung Hwa Son, Kwang-Kyun Park & Won-Yoon Chung. (2017) Artemisia annua extract prevents ovariectomy-induced bone loss by blocking receptor activator of nuclear factor kappa-B ligand-induced differentiation of osteoclasts. Scientific Reports 7:1.
Crossref
Crossref
Pit Jacob Voss, Akihiko Matsumoto, Esteban Alvarado, Rainer Schmelzeisen, Fabian Duttenhöfer & Philipp Poxleitner. (2017) Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells. Odontology 105:4, pages 484-493.
Crossref
Crossref
Sebastian Hoefert, Anna Yuan, Adelheid Munz, Martin Grimm, Ashraf Elayouti & Siegmar Reinert. (2017) Clinical course and therapeutic outcomes of operatively and non-operatively managed patients with denosumab-related osteonecrosis of the jaw (DRONJ). Journal of Cranio-Maxillofacial Surgery 45:4, pages 570-578.
Crossref
Crossref
Nam-Kyong Choi, Daniel H Solomon, Theodore N Tsacogianis, Joan E Landon, Hong Ji Song & Seoyoung C Kim. (2017) Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. Journal of Bone and Mineral Research 32:3, pages 611-617.
Crossref
Crossref
Akihiko Matsumoto, Masanori Sasaki, Rainer Schmelzeisen, Yukiko Oyama, Yoshihide Mori & Pit Jacob Voss. (2016) Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab. Clinical Oral Investigations 21:1, pages 127-134.
Crossref
Crossref
Chenglin Mo, Zhiying Wang, Lynda Bonewald & Marco Brotto. 2017. Bone Toxicology. Bone Toxicology
281
316
.
Ke Ke, Qi Li, Xiaofeng Yang, Zhijian Xie, Yu Wang, Jue Shi, Linfeng Chi, Weijian Xu, Lingling Hu & Huali Shi. (2016) Asperosaponin VI promotes bone marrow stromal cell osteogenic differentiation through the PI3K/AKT signaling pathway in an osteoporosis model. Scientific Reports 6:1.
Crossref
Crossref
Fabio Orlandi, Federico Arecco, Stefania Corvisieri & Ilaria Messuti. 2016. Primary, Secondary and Tertiary Hyperparathyroidism. Primary, Secondary and Tertiary Hyperparathyroidism
73
84
.
Eleni A. Georgakopoulou & Crispian Scully. (2015) Orofacial adverse effects of biological agents. Journal of Investigative and Clinical Dentistry 6:4, pages 252-260.
Crossref
Crossref
Polyzois Makras, Sideris Delaroudis & Athanasios D. Anastasilakis. (2015) Novel therapies for osteoporosis. Metabolism 64:10, pages 1199-1214.
Crossref
Crossref
Cornelia Then, Emmo von Tresckow, Reiner Bartl & Fuat S. Oduncu. 2015. Medication-Related Osteonecrosis of the Jaws. Medication-Related Osteonecrosis of the Jaws
17
26
.
Reiner Bartl & Emmo von Tresckow. 2015. Medication-Related Osteonecrosis of the Jaws. Medication-Related Osteonecrosis of the Jaws
1
15
.
M O'Halloran, NM Boyd & A Smith. (2014) Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases. Australian Dental Journal 59:4, pages 516-519.
Crossref
Crossref
R. Rizzoli, J. Branco, M.-L. Brandi, S. Boonen, O. Bruyère, P. Cacoub, C. Cooper, A. Diez-Perez, J. Duder, R. A. Fielding, N. C. Harvey, M. Hiligsmann, J. A. Kanis, J. Petermans, J. D. Ringe, Y. Tsouderos, J. Weinman & J.-Y. Reginster. (2014) Management of osteoporosis of the oldest old. Osteoporosis International 25:11, pages 2507-2529.
Crossref
Crossref
Abdul M Tyagi, Mohd N Mansoori, Kamini Srivastava, Mohd P Khan, Jyoti Kureel, Manisha Dixit, Priyanka Shukla, Ritu Trivedi, Naibedya Chattopadhyay & Divya Singh. (2014) Enhanced Immunoprotective Effects by Anti-IL-17 Antibody Translates to Improved Skeletal Parameters Under Estrogen Deficiency Compared With Anti-RANKL and Anti-TNF-α Antibodies. Journal of Bone and Mineral Research 29:9, pages 1981-1992.
Crossref
Crossref
P. Mosali, L. Bernard, J. Wajed, Z. Mohamed, M. Ewang, A. Moore, I. Fogelman & G. Hampson. (2014) Vitamin D Status and Parathyroid Hormone Concentrations Influence the Skeletal Response to Zoledronate and Denosumab. Calcified Tissue International 94:5, pages 553-559.
Crossref
Crossref
A. D. Anastasilakis, S. A. Polyzos, P. Makras, A. Gkiomisi, I. Bisbinas, A. Katsarou, A. Filippaios & C. S. Mantzoros. (2014) Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months. Osteoporosis International 25:5, pages 1633-1642.
Crossref
Crossref
Ben Antebi, Gadi Pelled & Dan Gazit. (2014) Stem Cell Therapy for Osteoporosis. Current Osteoporosis Reports 12:1, pages 41-47.
Crossref
Crossref
Polyzois Makras, Stergios A. Polyzos, Athanasios Papatheodorou, Panagiotis Kokkoris, Daniel Chatzifotiadis & Athanasios D. Anastasilakis. (2013) Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clinical Endocrinology 79:4, pages 499-503.
Crossref
Crossref
Tiziana Montalcini, Stefano Romeo, Yvelise Ferro, Valeria Migliaccio, Carmine Gazzaruso & Arturo Pujia. (2012) Osteoporosis in chronic inflammatory disease: the role of malnutrition. Endocrine 43:1, pages 59-64.
Crossref
Crossref